BioPharma Dive April 16, 2024
The biotech, previously known for its cancer work, is the latest company to change development plans in pursuit of a new type of lupus treatment.
Dive Brief:
- Cullinan Therapeutics said Tuesday that it’s expanding into autoimmune diseases such as lupus on the heels of promising research in the cell therapy field.
- As part of the new focus, the company shed its old name, Cullinan Oncology, and adopted a new logo and website address. Its stock will still trade under the symbol CGEM, and Cullinan will continue to develop a pipeline of cancer therapies as it pursues a wider range of indications.
- The company separately announced a private placement of about $274 million in stock at a price of $19...
Today's Sponsors
Today's Sponsor